SOURCES SOUGHT
A -- In Vitro Antiviral Screening System
- Notice Date
- 6/17/2002
- Notice Type
- Sources Sought
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institutes of Allergy and Infectious Diseases, Contract Management Branch 6700-B Rockledge Drive, MSC 7612 Room 2230, Bethesda, MD, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- Reference-Number-SS-M0306
- Response Due
- 6/28/2002
- Archive Date
- 7/13/2002
- Point of Contact
- Ross Kelley, Contract Specialist, Phone (301) 402-2234, Fax (301) 480-5253, - Paul McFarlane, Senior Contracting Officer, Phone 301-496-0349, Fax 301-402-0972,
- E-Mail Address
-
rk17a@nih.gov, pm24v@nih.gov
- Description
- The National Institute of Allergy and Infectious Diseases (NIAID) is seeking businesses with the capability of providing in vitro antiviral screening systems for one or more of the following viral categories (This announcement is not a request for proposals): (1)Herpes viruses: herpes simplex virus type 1 and type 2, varicella zoster virus, Epstein-Barr virus, human cytomegalovirus, human herpes virus-6, human herpes virus-7, and human herpes virus-8, (2)Respiratory viruses: influenza virus type A and type B, respiratory syncytial virus, parainfluenza virus type 3, measles virus, adenovirus type 5, and representatives of rhinoviruses, (3) Hepatitis B virus, (4) Hepatitis C virus, (5) Human papillomaviruses, (6) Orthopoxviruses: vaccinia virus, cowpox virus, and monkeypox virus, and (7) Biodefense pathogens (or their surrogates) that cause viral hemorrhagic fever and/or encephalitis. (For lists of biodefense pathogens, see http://www.bt.cdc.gov/agent/agentlist.asp and http://www.niaid.nih.gov/dmid/bioterrorism/bandc_priority.htm) The businesses or organizations we are seeking must have the ability to provide viral screens for one or more of the categories listed and should have the ability to screen for all of the viruses within a viral category. The objective of these in vitro screens would be multi-faceted: (1) selective indexes of potential antiviral compounds are determined to guide the selection and prioritization of compounds for evaluations in animal models; (2) active compounds are further evaluated against additional virus strains including clinical and drug-resistant isolates to explore their clinical potential; (3) studies on mechanisms of action and drug combinations are conducted to better understand compounds' pharmacological properties, as well as potential utilization and limitations (e.g., virustatic vs. virucidal activity, systemic vs. topical treatment, synergistic vs. antagonistic drug interaction); and (4) research also is conducted to improve the current screening systems, to develop automated high-throughput screening systems, and to adopt new assays. There is no RFP available and the government is not committed to award a contract pursuant to this Sources Sought Notice. Responses should not include cost or pricing information. PLEASE NOTE: if a solicitation were issued, NIAID would seek approval of a deviation to the standard text within FAR clause 52.227-11 Patent Rights - Retention by the Contractor (Short Form) (June 1997) from DHHS and would obtain clearance from OD, NIH to allow its use in any resultant contract. Also, NIAID would seek approval of a deviation to the standard text within FAR clause 52.227-14 Rights in Data - General (June 1987) from DHHS. The deviation to FAR 52.227-11 will allow those third party compound suppliers who permit the Division of Microbiology and Infectious Diseases to test their compound under contract, to have the right to any subject inventions related to their compounds. The deviation to FAR 52.227-11 would delay the Contractor's publication of the research results related to third party compounds, thus allowing time for the compound supplier(s) to prepare and file patent applications. In addition, if a solicitation were issued and a contract were awarded, the Government may require the use of Screening Agreements or Material Transfer Agreements between the NIAID and providers of compounds in order to protect the intellectual property rights of third party compound suppliers. The Offeror must provide documentation of its capabilities to perform the duties described below. (1)Provide validated screening systems for all of the selected viruses. Conduct evaluation on experimental antiviral substances using proven assays. a. Determine the inhibitory effect on virus replication and/or infectivity based on meaningful endpoints to determine effective and cytotoxic concentrations and selective indexes. b. Determine the inhibitory effect against other virus strains (e.g., clinical isolates, drug-resistant strains) in appropriate cell lines for compounds with reasonable selective antiviral activity. (2)Perform special studies as directed by the Project Officer, which shall include, but are not restricted to, combination drug testing, mechanism of action studies targeting specific steps in viral replication, and other more detailed testing. Assays pertinent to special studies shall be designed, developed, compared to existing assays, standardized, validated and performed, as necessary. (3)Evaluate and develop new in vitro testing systems at the direction of the Project Officer. (4)Receive, Store, and Record substances for testing. a. Maintain and store frozen stocks of compounds in a sterile manner. b. Maintain a master list of compounds received for testing, freezer location, usage, and other pertinent information. (5)Conduct work in accordance with all applicable Federal, State, and Local safety and health guidelines and regulations regarding to exposure to hazardous chemicals and potentially harmful and/or infectious biological materials. (6)Provide appropriate biosafety laboratory (for reference see, Biosafety in Microbiological and biomedical Laboratories, 4th Ed., May 1999, by CDC and NIH). (7)Provide qualified management and technical personnel.
- Record
- SN00094484-W 20020619/020617213211 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |